Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.

High Staphylococcus epidermidis Colonization and Impaired Permeability Barrier in Facial Seborrheic Dermatitis. Chin Med J (Engl) (2017) 0.75

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol (2001) 1.75

Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol (2004) 1.68

Differentiation of Malassezia species: selectivity of cremophor EL, castor oil and ricinoleic acid for M. furfur. Br J Dermatol (1997) 1.57

Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol (2003) 1.55

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol (2001) 1.08

Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol (2006) 1.08

Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol (2001) 1.08

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm (2004) 1.07

Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (2002) 1.06

Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol (2011) 1.02

First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol (2001) 0.96

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child (2003) 0.96

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol (1999) 0.95

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology (2005) 0.93

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol (2007) 0.91

Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res (1996) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol (2009) 0.89

Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol (2004) 0.88

Pimecrolimus -- an anti-inflammatory drug targeting the skin. Exp Dermatol (2004) 0.87

Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol (2012) 0.86

An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol (2003) 0.86

An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol (2009) 0.84

Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Pediatr Dermatol (2005) 0.84

A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology (2002) 0.83

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol (2006) 0.83

Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res (2004) 0.81

Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J (2003) 0.81

Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol (2008) 0.80

Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract (2003) 0.80

An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol (2007) 0.79

Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol (2006) 0.79

Dermatophytes contain a novel lipid-like leukocyte activator. J Invest Dermatol (1996) 0.78

Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Arch Dermatol (2004) 0.76